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| INTRODUC TI ON
Catheter ablation for atrial fibrillation (AF) has become a widely used approach for the treatment of symptomatic, drug-refractory AF.
1,2 A form of ablative energy is delivered through a catheter introduced into the atria via the venous vasculature to create scar and disrupt the postulated underlying arrhythmogenic substrate.
Because the currently utilized energy forms of heating via radiofrequency energy or cooling via a balloon-delivered freezant require direct contact with the myocardial target, an invasive approach is required. The mainstay approach for catheter ablation for AF continues to be a durable electrical isolation of the pulmonary veins, 1,2 while appropriate and effective ablation targets beyond the pulmonary veins, particularly in patients with persistent AF, remain poorly defined.
Freedom from recurrent AF after catheter ablation varies widely, with reported arrhythmia-free survival ranging from as low as 20%
to as high as 95%. 1, 2 Several variables likely impact outcomes, including AF substrate (paroxysmal vs persistent AF), underlying cardiac pathology, the ablation technique and lesion set utilized, and the methods used to monitor AF burden and recurrence. Although catheter ablation is a reasonably safe and effective procedure, there are well-established risks of complications, including vascular injury, cardiac perforation, phrenic nerve injury, stroke, and most concerning, atrioesophageal fistula, which portend a high mortality rate.
1,2
As a result, there is ongoing interest in developing improved therapies for AF.
Stereotactic body radiation therapy (SBRT) is a technology
widely used to primarily treat malignancies and functional disorders. 3 Ionizing radiation in the form of photon energy is delivered to the target tissue via an external beam delivery system. The energy is delivered either by a source that is mounted on a robotically controlled arm or gantry that moves quickly around the patient. Up to several hundred high-energy beams are delivered at varying vectors to concentrate ablative energy within the target while sparing the surrounding tissues. Treatment delivery planning is based on imaging of the target with designation of a treatment zone using software associated with the delivery system. The software typically converts the physician's rendered plan into a radiation delivery protocol which then is delivered in a treatment suite under the direction of a radiation oncologist and radiation physicist. Stereotactic radioablation has been used to successfully treat a wide array of solid tumors including intrathoracic malignancies at an acceptable risk for collateral toxicity. [4] [5] [6] The successful adaptation of stereotactic radioablation to target cardiac substrates has been reported. [7] [8] [9] The challenge of effective and safe ablative energy delivery to cardiac tissues is heightened because of the target motion resulting from both respiration and the cardiac contractile cycle. Despite this, effective and safe ablation has been reported in treating human intracardiac malignancy. 7 In a porcine model, the AV node and cavotricuspid isthmus have been targeted successfully, with demonstration of resultant conduction block. 8, 10 More recently, successful clinical treatment of left ventricular myocardial substrate for malignant ventricular tachycardia has also been reported. 9, 11, 12 However, these prior applications of SBRT required a volumetrically simple target; essentially, a spheroid contour was desired.
Whereas, the task of creating electrical isolation of the pulmonary veins requires a significantly more complex treatment volume if the current approach of wide-area antral pulmonary vein ablation remains the goal. Despite this complexity, the technology for delivering SBRT has, in theory, the inherent ability to translate any arbitrary treatment volume geometry imagined by the physician into reality in an automated fashion. As proof of this principle, in a canine and porcine model, targeting the right superior pulmonary vein with SBRT demonstrated dose-dependent efficacy in achieving electrophysiological conduction disruption and histological treatment effect. 13 Safe and effective delivery of stereotactic radioablation to the left atrium (LA) in humans has not yet been reported. We postulated that a standard, widely clinically utilized stereotactic radioablation system could be configured to deliver safe and effective therapy to the LA to target the pulmonary veins in patients with drug-refractory paroxysmal AF. 
| ME THODS

| Stereotactic radioablation treatment planning
The patients were treated in an ambulatory setting without interruption of antiarrhythmic medications or anticoagulation. In order to optimize target tracking during cardiorespiratory motion, an internal fiducial marker was placed transvenously in proximity to the left atrial target, specifically at the right atrial septum. Under fluoroscopic guidance and via right internal jugular vein vascular access obtained using Seldinger technique, an active fixation unipolar pacing lead (Oscor, 6 French) was introduced into the right atrium and attached to the interatrial septum ( Figure 1 ). In this fashion, no specific movement or breathing restrictions were required of the patients during treatment.
With the fiducial marker in place, patients underwent a planning contrast-enhanced cardiac computed tomography (CT) of the LA. A three-dimensional rendering of the LA was created using cardiac-specific contouring software (CardioPlan, Cyberheart) and used for identifying the treatment target. This target was then imported into the treatment planning software associated with the treatment system (CyberKnife, Accuray) and used to create the radiosurgical treatment plan. In this paradigm, the contouring software allowed the electrophysiologist to draw a computer rendering of the desired treatment volume. Once an acceptable graphic rendering of the treatment volume was created, the treatment planning software in turn then calculated the appropriate delivered radiation beams and their vectors.
Next, the treatment plan was evaluated and modified as needed by a radiation oncologist, radiation physicist, and radiation therapist.
| Stereotactic radioablation treatment delivery
Treatment simulations were performed to ensure therapeutic radiation delivery of >25 Gy to the intended target without exceeding a maximum dose of 35 Gy, based on previous treatment experience, 9, 11 while assurance of dosing within tolerances for surrounding structures. 14 The patient was then placed supine on the treatment platform and SBRT was delivered. Real-time imaging with planar x-rays was utilized to register the treatment plan using the fiducial marker as guidance. Next, the therapy was delivered as planned over the prescribed time course of approximately 90 minutes. No procedural sedation was required. Breaks in treatment were provided as needed for the patients, although none were needed. Immediately after treatment delivery, the fiducial marker was removed, and the patients were discharged home. 
| Clinical follow-up
| RE SULTS
Two patients, a 59-year-old man (patient 1) and a 55-year-old woman (patient 2), were treated. Baseline demographics for each patient are shown in Table 1 . Both patients had paroxysmal, symptomatic, and drug-refractory AF; minimal comorbidities, save stroke in one patient, and hypertension in the other. Left ventricle (LV) function was normal, LA size was normal or mildly enlarged, and no valvular heart disease was present. Patients were both anticoagulated with direct oral anticoagulant (DOAC) agents, and neither had undergone prior cardioversion or catheter ablation.
| Design of the stereotactic radioablation lesion set
Radioablation treatment parameters for both patients are shown in Table 2 . The designed lesion set for pulmonary vein isolation aimed to minimize radiation dosing to surrounding structures, in particular, the esophagus. The phrenic nerve could not be confidently identified on imaging. However, the (Figures 2 and 3 ). These lesion sets were designed principally to minimize radiation dosing to the esophagus.
| Delivery of radioablation dose
After fiducial marker placement and CT scan were performed, treatment planning and radioablative energy delivery was completed within 2 hours. The intended treatment plan was successfully delivered for both patients, with 89% and 96% of the planned treatment volumes receiving ≥25 Gy for patient 1 and 2, respectively ( Figure 3) , and acceptable average dose to nearby visceral tissues 14 ( Table 2 ; Figure 3 ).
Immediately after treatment, the fiducial markers were removed without complication. The patients tolerated the procedure well, with no immediate physical complaints nor observed complications.
| Clinical follow-up
In patient 1, no AF recurrence was seen during the first 6 months of follow-up; however, persistent AF occurred at 6 months.
Because of prior intolerance of beta-blocker, the patient was placed on a rate control regimen of diltiazem. Owing to patient preference, no further attempts at rhythm control were performed. For patient 2, no recurrence of AF was seen on follow-up and monitoring. The patient continued on propafenone, having For patient 2, a cardiac MRI was performed before and at 1 year after SBRT delivery which showed a region of fibrosis not present on baseline imaging (Figure 4 ). The distribution of fibrosis in the septal and lateral left atrial walls was consistent with the SBRT lesion set delivered in this patient (Figures 1 and 2) . No symptomatic nor occult complications were observed throughout the entire follow-up period to date and no change in cardiac function or valvular heart disease was observed (Table 3 ).
TA B L E 1 Baseline clinical characteristics of the treated patients
| D ISCUSS I ON
In this study, first-in-man treatment of paroxysmal AF using stereotactic radioablation is described in two patients with indications for catheter ablation but a strong desire to undergo a less invasive procedure. We showed that it is possible to coordinate, plan, and accurately deliver a complex lesion set to the LA using stereotactic ablative therapy safely and effectively with a multidisciplinary team that includes cardiologists, electrophysiologists, and radiation oncologists and radiation physicists. No complications or longer term side effects of cardiac tissue irradiation were observed in either patient; one patient had reduction in AF burden and subsequent MRI imaging was consistent with left atrial radioablation induced fibrosis.
Atrial fibrillation continues to be one of the fastest growing, most prevalent, and costly cardiac conditions. 2 Treatments directed at restoration and maintenance of sinus rhythm remain inadequate both in long-term single-procedure success rates 
| LI M ITATI O N S
The small number of treated patients limit generalizability of the observed results and more clinical experience is warranted to better understand the efficacy and safety of this treatment paradigm.
Given patient preference in this study, invasive electrophysiologic testing could not be performed to demonstrate electrical block.
Further studies in larger patient cohorts and where pulmonary vein isolation can be ascertained are required to overcome these limitations.
| CON CLUS ION
In this first-in-man study, we demonstrated the feasibility of applying SBRT to accurately deliver a complex left atrial lesion set aiming to isolate the pulmonary veins and posterior wall in patients with symptomatic paroxysmal AF. Stereotactic radioablation is a widely available technology that can potentially provide a noninvasive alternative for delivering ablation therapy to control this highly prevalent and important condition. The translation to clinical practice of this imminently scalable approach depends on further studies to define optimal clinical dosing, procedural efficacy, and long-term safety.
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